Journal ArticleDOI
Priorities in Parkinson's disease research
Wassilios G. Meissner,Wassilios G. Meissner,Mark Frasier,Thomas Gasser,Christopher G. Goetz,Andres M. Lozano,Paola Piccini,Jose A. Obeso,Olivier Rascol,Anthony H.V. Schapira,Valerie Voon,David M. Weiner,François Tison,François Tison,Erwan Bezard +14 more
Reads0
Chats0
TLDR
This Review describes the most promising biological targets and therapeutic agents that are currently being assessed to address treatment goals of Parkinson's disease.Abstract:
The loss of dopaminergic neurons in the substantia nigra pars compacta leads to the characteristic motor symptoms of Parkinson's disease: bradykinesia, rigidity and resting tremors. Although these symptoms can be improved using currently available dopamine replacement strategies, there is still a need to improve current strategies of treating these symptoms, together with a need to alleviate non-motor symptoms of the disease. Moreover, treatments that provide neuroprotection and/or disease-modifying effects remain an urgent unmet clinical need. This Review describes the most promising biological targets and therapeutic agents that are currently being assessed to address these treatment goals. Progress will rely on understanding genetic mutations or susceptibility factors that lead to Parkinson's disease, better translation between preclinical animal models and clinical research, and improving the design of future clinical trials.read more
Citations
More filters
Journal ArticleDOI
N-Propargyl Caffeate Amide (PACA) Potentiates Nerve Growth Factor (NGF)-Induced Neurite Outgrowth and Attenuates 6-Hydroxydopamine (6-OHDA)-Induced Toxicity by Activating the Nrf2/HO-1 Pathway
TL;DR: It is discovered that PACA not only potentiated NGF-induced neurite outgrowth but also attenuated 6-hydroxydopamine (6-OHDA) neurotoxicity in dopaminergic PC12 cells and primary rat midbrain neurons, suggesting that PAC a may exhibit neuroprotective and neuritogenic activities via activating the Nrf2/HO-1 antioxidant pathway.
Journal ArticleDOI
Lycopodium Attenuates Loss of Dopaminergic Neurons by Suppressing Oxidative Stress and Neuroinflammation in a Rat Model of Parkinson's Disease.
Richard L. Jayaraj,Rami Beiram,Sheikh Azimullah,Mohamed Fizur Nagoor Meeran,Shreesh Ojha,Abdu Adem,Fakhreya Y Jalal +6 more
TL;DR: Robtenone-injected rats that were orally treated with lycopodium were protected against dopaminergic neuronal loss by diminishing the expression of matrix metalloproteinase-3 and MMP-3, as well as reduced activation of microglia and astrocytes, suggesting that Lyc has the potential to be further developed as a therapeutic candidate for PD.
Journal ArticleDOI
Antidyskinetic Effect of 7-Nitroindazole and Sodium Nitroprusside Associated with Amantadine in a Rat Model of Parkinson's Disease.
Mariza Bortolanza,Keila Bariotto-dos-Santos,Maurício dos-Santos-Pereira,C.A. da-Silva,Elaine Del-Bel +4 more
TL;DR: Combining ineffective doses of amantadine and 7NI represents a new strategy to increase antidyskinetic effect in l-DOPA-induced AIMs and may provide additional therapeutic benefits to Parkinson’s disease patients from these disabling complications at lower and thus safer and more tolerable doses than required when either drug is used alone.
Journal ArticleDOI
Functional and Neuroprotective Role of Striatal Adenosine A2A Receptor Heterotetramers.
Sergi Ferré,Francisco Ciruela +1 more
TL;DR: It is hypothesized that alterations in the homomer/heteromer stoichiometry (i.e., increase or decrease in the proportion of A2AR forming homomers or heteromers) are pathogenetically involved in neurological disorders, specifically in Parkinson's disease and restless legs syndrome.
Journal ArticleDOI
Upgraded Methodology for the Development of Early Diagnosis of Parkinson's Disease Based on Searching Blood Markers in Patients and Experimental Models
A.A. Kim,R. R. Nigmatullina,Zuleikha A Zalyalova,Natalia V. Soshnikova,A. N. Krasnov,Nadezhda E. Vorobyeva,Sofia G. Georgieva,Sofia G. Georgieva,V. S. Kudrin,Viktor B. Narkevich,Michael V. Ugrumov,Michael V. Ugrumov +11 more
TL;DR: It was shown that among 13 blood markers found in patients, 7 markers are characteristic of parkinsonian symptomatic mice and 3 markers of both symptomatic and presymptomatic mice are suitable for early diagnosis of PD.
References
More filters
Journal ArticleDOI
Parkinson’s disease: clinical features and diagnosis
TL;DR: A thorough understanding of the broad spectrum of clinical manifestations of PD is essential to the proper diagnosis of the disease and genetic mutations or variants, neuroimaging abnormalities and other tests are potential biomarkers that may improve diagnosis and allow the identification of persons at risk.
Journal ArticleDOI
Diagnosis and management of dementia with Lewy bodies: Third report of the DLB Consortium
Ian G. McKeith,Ian G. McKeith,Dennis W. Dickson,James Lowe,Murat Emre,John T. O'Brien,Howard Feldman,Jeffrey L. Cummings,John E. Duda,Carol F. Lippa,Elaine K. Perry,Dag Aarsland,Hiroyuki Arai,Clive Ballard,B. F. Boeve,David J. Burn,Durval C. Costa,T. Del Ser,Bruno Dubois,Douglas Galasko,Serge Gauthier,Christopher G. Goetz,Estrella Gómez-Tortosa,Glenda M. Halliday,L. A. Hansen,John Hardy,Takeshi Iwatsubo,Raj N. Kalaria,Daniel I. Kaufer,Rose Anne Kenny,Amos D. Korczyn,Kenji Kosaka,Virginia M.-Y. Lee,Andrew J. Lees,Irene Litvan,Elisabet Londos,Oscar L. Lopez,Satoshi Minoshima,Yoshikuni Mizuno,José Antonio Molina,Elizabeta B. Mukaetova-Ladinska,Florence Pasquier,Robert H. Perry,Jörg B. Schulz,John Q. Trojanowski,Masahito Yamada +45 more
TL;DR: The dementia with Lewy bodies (DLB) Consortium has revised criteria for the clinical and pathologic diagnosis of DLB incorporating new information about the core clinical features and suggesting improved methods to assess them as mentioned in this paper.
Journal ArticleDOI
α-Synuclein Locus Triplication Causes Parkinson's Disease
Andrew B. Singleton,Matthew J. Farrer,Joshua C. Johnson,Amanda Singleton,Stephen Hague,Jennifer M. Kachergus,Mary M. Hulihan,Terhi Peuralinna,Amalia Dutra,Robert L. Nussbaum,Sarah Lincoln,Anthony Crawley,Melissa Hanson,Demetrius M. Maraganore,Charles H. Adler,Mark R. Cookson,Manfred D. Muenter,Melisa J. Baptista,David Miller,J. Blancato,John Hardy,Katrina Gwinn-Hardy +21 more
TL;DR: In this article, the α-synuclein was identified as the major component of Lewy bodies, the pathological hallmark of Parkinson's disease, and of glial cell cytoplasmic inclusions.
Related Papers (5)
Mutation in the α-synuclein gene identified in families with Parkinson's disease
Mihael H. Polymeropoulos,Christian Lavedan,Elisabeth Leroy,Susan E. Ide,Anindya Dehejia,Amalia Dutra,Brian L. Pike,Holly Root,Jeffrey Rubenstein,Rebecca Boyer,Edward S. Stenroos,Settara C. Chandrasekharappa,Aglaia Athanassiadou,Theodore Papapetropoulos,William G. Johnson,Alice Lazzarini,Roger C. Duvoisin,Giuseppe Di Iorio,Lawrence I. Golbe,Robert L. Nussbaum +19 more